Eagle Pharmaceuticals, Inc. (EGRX)
OTCMKTS · Delayed Price · Currency is USD
1.000
0.00 (0.00%)
Oct 23, 2025, 8:00 PM EDT
Eagle Pharmaceuticals Revenue
Eagle Pharmaceuticals had revenue of $64.65M in the quarter ending June 30, 2023, a decrease of -12.80%. This brings the company's revenue in the last twelve months to $257.55M, down -5.38% year-over-year. In the year 2022, Eagle Pharmaceuticals had annual revenue of $316.61M with 84.56% growth.
Revenue (ttm)
257.55M
Revenue Growth
-5.38%
P/S Ratio
0.05
Revenue / Employee
1.92M
Employees
134
Market Cap
13.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 316.61M | 145.06M | 84.56% |
| Dec 31, 2021 | 171.55M | -16.26M | -8.66% |
| Dec 31, 2020 | 187.80M | -8.09M | -4.13% |
| Dec 31, 2019 | 195.89M | -17.42M | -8.17% |
| Dec 31, 2018 | 213.31M | -23.40M | -9.88% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Eagle Pharmaceuticals News
- 10 days ago - Eagle Pharmaceuticals GAAP EPS of -$0.12, revenue of $48.71M - Seeking Alpha
- 11 days ago - Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements - GlobeNewsWire
- 19 days ago - Eagle Pharmaceuticals GAAP EPS of -$3.88, revenue of $37.27M - Seeking Alpha
- 20 days ago - Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements - GlobeNewsWire
- 5 weeks ago - Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years - GlobeNewsWire
- 2 months ago - Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors - GlobeNewsWire
- 2 months ago - Eagle Pharmaceuticals Announces 2025 Annual Meeting Date - GlobeNewsWire
- 7 months ago - Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties - Benzinga